Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inamed's 2.5 Mil. Share Secondary Offering Expected To Net $60 Mil.

This article was originally published in The Gray Sheet

Executive Summary

Proceeds from Inamed's secondary 2.5 mil. share stock offering will go toward significantly reducing the $155 mil. in outstanding debt under the company's bridge loan facility.

You may also be interested in...



Inamed To Finalize $142 Mil. Collagen Aesthetics Acquisition By Oct. 1

Inamed is looking to build a $225 mil. global plastic and aesthetic surgery device business through the acquisition of Palo Alto, California-based Collagen Aesthetics.

ATS Licenses Tissue Technology To Inamed For Cosmetic Applications

Advanced Tissue Sciences and Inamed expect to market a tissue-engineered product for healing skin following laser peel procedures by the end of the year, under a strategic alliance announced May 12.

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel